DDW Editor Reece Armstrong speaks to Roger Levy, Global Medical Expert Immunology & Specialty Medicine at GSK about the company’s work into treating systemic sclerosis-associated interstitial lung disease and its recent BLISSc-ILD study evaluating its belimumab treatment. RA: Can you give us an overview of the BLISSc-ILD study? RL: The BLISSc-ILD study is a randomised, double-blind, placebo-controlled, […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!